Pharma Industry News

A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.

globenewswire.com - Zealand Pharma - Zealand Pharma to present additional data from Phase 2 ZUPREME-1 trial for petrelintide at EASD 2026 and announces publication of trial results in The Lancet Diabetes & Endocrinology
Zealand Pharma to present additional data from Phase 2 ZUPREME-1 trial for petrelintide at EASD 2026 and announces publication of trial results in The Lancet Diabetes & Endocrinology
GlobeNewswire –

Press release – No. 18 / 2026 Zealand Pharma to present additional data from Phase 2 ZUPREME-1 trial for petrelintide at EASD 2026 and announces publication of trial results in The Lancet Diabetes & Endocrinology Treatment with petrelintide…

globenewswire.com - Novo Nordisk A/S - Novo and Hengrui Pharma enter exclusive license agreement for once-weekly oral GLP-1/GIP dual receptor agonist HRS-1596
Novo and Hengrui Pharma enter exclusive license agreement for once-weekly oral GLP-1/GIP dual receptor agonist HRS-1596
GlobeNewswire –

HRS-1596 is a phase 1-ready GLP-1/GIP dual receptor agonist for once-weekly oral dosing Total potential deal value is up to 2.6 billion US dollars, including 300 million dollars upfront, as well as potential sales royalties Bagsværd, Denmark…

prnewswire.com - Piramal Pharma Solutions - Ontario Contributes $1.7 Million Investment to Advance Life Sciences Innovation at Piramal Pharma's Aurora Facility
Ontario Contributes $1.7 Million Investment to Advance Life Sciences Innovation at Piramal Pharma's Aurora Facility
Cision PR Newswire –

With support from the government of Ontario, Piramal Pharma is investing $5,314,000 to upgrade site infrastructure at their Aurora facility, strengthening Ontario's pharmaceutical manufacturing and bolstering domestic production of APIs. This…

republicworld.com - Shruti Sneha - India Gets US Pharma Tariff Exemption, But Which Drugs Still Face Trump's 100% Duty?
India Gets US Pharma Tariff Exemption, But Which Drugs Still Face Trump's 100% Duty?
Republic World –

Washington: The United States has exempted select pharmaceutical products and related components originating from India and 19 other partner jurisdictions from import duties, even as Washington moves ahead with a 100 per cent tariff on specified…

thehindu.com - Gayatri Saberwal - Why rare-disease drugs could become India's next pharma frontier
Why rare-disease drugs could become India's next pharma frontier
The Hindu –

Each rare disease affects very few people. However, there are around 8,000 rare diseases, and they cumulatively affect hundreds of millions of people. In India, 1,004 rare genetic disorders have been reported so far. It used to be that because the…

seekingalpha.com - SA Transcripts - Roche Holding AG (RHHBY) Discusses Pharma Strategy, R&D Excellence, AI in Drug Development, and Pipeline Updates Across Key Therapeutic Areas Transcript
Roche Holding AG (RHHBY) Discusses Pharma Strategy, R&D Excellence, AI in Drug Development, and Pipeline Updates Across Key Therapeutic Areas Transcript
Seeking Alpha –

Roche Holding AG (RHHBY) Discusses Pharma Strategy, R&D Excellence, AI in Drug Development, and Pipeline Updates Across Key Therapeutic Areas September 28, 2026 4:30 AM EDT Bruno Eschli - Head of Investor Relations Teresa Graham - Chief Executive…

thehindubusinessline.com - Surat-based Anupam Rasayan completes ₹1,750-cr acquisition of 48.2% in Bliss GVS Pharma
Surat-based Anupam Rasayan completes ₹1,750-cr acquisition of 48.2% in Bliss GVS Pharma
BusinessLine –

Surat-based Anupam Rasayan India has completed the acquisition of a 48.2 per cent controlling stake in Bliss GVS Pharma for a total acquisition outlay of ₹1,750 crore, marking its third strategic inorganic transaction, as the Surat-based…

thehindubusinessline.com - Natco Pharma raises eGenesis investment to $16.70 million
Natco Pharma raises eGenesis investment to $16.70 million
BusinessLine –

Natco Pharma Ltd on Monday said it has decided to increase its proposed investment in US-based biotechnology firm eGenesis Inc to USD 16.70 million (around Rs 139 crore) from the previously disclosed amount of USD 14 million. Under the revised…

marketbeat.com - Spyglass Pharma (NASDAQ:SGP) Shares Down 4.5% - What's Next?
Spyglass Pharma (NASDAQ:SGP) Shares Down 4.5% - What's Next?
MarketBeat –

Spyglass Pharma, Inc. (NASDAQ:SGP - Get Free Report)'s share price fell 4.5% during trading on Tuesday. The company traded as low as $24.93 and last traded at $24.8110. 19,056 shares were traded during mid-day trading, a decline of 83% from the…

thehindubusinessline.com - Anupam Rasayan completes purchase of 48.2 pc stake in Bliss GVS Pharma for ₹1,750 cr
Anupam Rasayan completes purchase of 48.2 pc stake in Bliss GVS Pharma for ₹1,750 cr
BusinessLine –

Specialty chemicals maker Anupam Rasayan India on Tuesday said it has completed the acquisition of a 48.2 per cent controlling stake in Bliss GVS Pharma for ₹1,750 crore, marking its push into finished dosage formulations. It is Anupam…

cbsnews.com - Kaia  Hubbard - Democrat Abdul El-Sayed courts RFK Jr.'s MAHA voters with new health policy platform
Democrat Abdul El-Sayed courts RFK Jr.'s MAHA voters with new health policy platform
CBS News –

Washington — Michigan Democratic Senate candidate Abdul El-Sayed is making a play for Robert F. Kennedy Jr.'s 'Make America Healthy Again' supporters with the release Tuesday of a new health policy platform. 'I think we have an opportunity…

prnewswire.com - VALITIC™ Expands Retail Industry Visibility Through Shoptalk Fall 2026 in Nashville, USA
VALITIC™ Expands Retail Industry Visibility Through Shoptalk Fall 2026 in Nashville, USA
Cision PR Newswire –

HERZLIYA, Israel and CALGARY, Alberta, Sept. 29, 2026 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (OTCQB: INNPF) ('Innocan' or the 'Company'), through B.I. Sky Global Ltd., its consumer wellness subsidiary, is pleased to announce that…

marketbeat.com - Nuvectis Pharma, Inc. (NASDAQ:NVCT) Stock Has Consensus Target Price of $36.25 According to Brokerages
Nuvectis Pharma, Inc. (NASDAQ:NVCT) Stock Has Consensus Target Price of $36.25 According to Brokerages
MarketBeat –

Shares of Nuvectis Pharma, Inc. (NASDAQ:NVCT - Get Free Report) have been given a consensus recommendation of 'Moderate Buy' by the five research firms that are presently covering the company, MarketBeat Ratings reports. One investment analyst has…

rediff.com - Rediff News - Stock markets tumble in early trade
Stock markets tumble in early trade
Rediff.com –

Equity benchmark indices Sensex and Nifty tumbled in early trade on Tuesday as elevated crude oil prices due to uncertainty over the West Asia situation and foreign fund outflows weighed on investors' sentiment. The 30-share BSE Sensex dropped 503…

indianexpress.com - Akash Mandal - Stocks down again - but what are the outliers in India's share market slide?
Stocks down again - but what are the outliers in India's share market slide?
The Indian Express –

A host of pharmaceutical players, particularly contract development and manufacturing organisations (CDMOs), have boomed over the past few months. Despite being down around 1% in September, the Nifty Pharma index is up 6% over the past three months…

Receive a Daily briefing on Pharma Industry News

Get Started